1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012. 62:10–29.
2. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006. 66:1285–1291.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012. 62:283–298.
4. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta Oncol. 1991. 30:133–140.
5. Barnholtz-Sloan JS, Raska P, Rebbeck TR, Millikan RC. Replication of GWAS "Hits" by Race for Breast and Prostate Cancers in European Americans and African Americans. Front Genet. 2011. 2:37.
6. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012. 10:1081–1087.
7. Steers WD. 5alpha-reductase activity in the prostate. Urology. 2001. 58:6 Suppl 1. 17–24.
8. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008. 99:81–86.
9. Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy. 1993. 13:309–325.
10. Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, et al. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol. 2012. 12. 04. [Epub].
http://dx.doi.org/10.1007/s00345-012-1000-4.
11. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005. 63:231–239.
12. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate. 2003. 57:134–139.
13. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004. 172(4 Pt 1):1399–1403.
14. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, et al. 5a-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011. 71:1033–1046.
15. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, et al. Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011. 6:e28840.
16. Riley DE, Krieger JN. Short tandem repeat (STR) replacements in UTRs and introns suggest an important role for certain STRs in gene expression and disease. Gene. 2005. 344:203–211.
17. Riley DE, Krieger JN. Short tandem repeats are associated with diverse mRNAs encoding membrane-targeted proteins. Bioessays. 2004. 26:434–444.
18. Riley DE, Krieger JN. Transcribed short tandem repeats occur in couples with strongly preferred registers. Biochem Biophys Res Commun. 2003. 305:257–265.
19. Kleiman FE, Ramirez AO, Dodelson de, Gravel RA, Argarana CE. A frequent TG deletion near the polyadenylation signal of the human HEXB gene: occurrence of an irregular DNA structure and conserved nucleotide sequence motif in the 3' untranslated region. Hum Mutat. 1998. 12:320–329.
20. Riley DE, Krieger JN. Diverse eukaryotic transcripts suggest short tandem repeats have cellular functions. Biochem Biophys Res Commun. 2002. 298:581–586.
21. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012. 72:6142–6152.